SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27307)1/8/1999 3:09:00 AM
From: Jongmans  Read Replies (1) | Respond to of 32384
 
Dr Niman, may I please draw your attention

Dr Niman, may I please draw your attention to:

Message 7157651

regarding the immunity-question (ARIAD-UOP)

You are certainly the expert in this matter. Acting as our intermediary to put these question to Gilman of Wilson will give us the best answer possible.

Most readers of your messages on this matter would be thankfull.

Best regards and many thanks,

Martin



To: Henry Niman who wrote (27307)1/9/1999 6:43:00 PM
From: Len  Respond to of 32384
 
Henry,
Do you know where I could get a schedule of the presentations at the H&Q conference next week?

Thanks.

Len Myers



To: Henry Niman who wrote (27307)1/11/1999 12:35:00 PM
From: Paul Moerman  Read Replies (3) | Respond to of 32384
 
Henry and thread: I just opened the Jan 8 Kiplinger Washingon Letter and there's an insert (Personal Finance Advisor) giving favorable mention to Chiron, Ligand, and Pathogenesis as companies to consider in the biotech field!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News